Upbeat about downbeat nystagmus.
G Michael
GM
Halmagyi
R John
RJ
Leigh
D015761:4-Aminopyridine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D000077770:Amifampridine; D000818:Animals; D015220:Calcium Channels / Q000172:deficiency / Q000235:genetics / Q000502:physiology; D020864:Calcium Channels, N-Type; D020865:Calcium Channels, P-Type; D020907:Calcium Channels, Q-Type; D002525:Cerebellar Cortex / Q000187:drug effects / Q000503:physiopathology; D005260:Female; D006112:Gravitation; D000882:Haplorhini; D006801:Humans; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D008959:Models, Neurological; D009759:Nystagmus, Pathologic / Q000188:drug therapy / Q000503:physiopathology*; D010037:Otolithic Membrane / Q000503:physiopathology; D026902:Potassium Channel Blockers / Q000494:pharmacology / Q000627:therapeutic use; D012021:Reflex, Abnormal; D012027:Reflex, Vestibulo-Ocular / Q000502:physiology
D015761:4-Aminopyridine; D000077770:Amifampridine; D015220:Calcium Channels; D020864:Calcium Channels, N-Type; D020865:Calcium Channels, P-Type; D020907:Calcium Channels, Q-Type; D026902:Potassium Channel Blockers; C105656:CACNA1A protein, human